Clinical Features Of Respiratory Viral Infections During 2009 Influenza A(H1N1) Epidemic Period

2011 ◽  
Author(s):  
Jin-A Jung ◽  
Hye-Sung An ◽  
Eun-Jeong Choi ◽  
Hyun-Jin Yun ◽  
Ja-Hyung Kim
Keyword(s):  
Clinical Features ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza A H1n1 ◽  
Epidemic Period ◽  
Respiratory Viral Infections

scholarly journals ЕPIDEMIOLOGICAL AND СLINICAL FEATURES OF INFLUENZA IN CHILDREN IN THE STAVROPOL TERRITORY IN THE EPIDEMIC PERIOD OF 2015–2016 AND 2016–2017 YEARS

2019 ◽  
Vol 11 (1) ◽  
pp. 71-75
Author(s):  
S. M. Bezrodnova ◽  
N. A. Yatsenko ◽  
O. O. Kravchenko ◽  
Sh. M. Khurtsilava
Keyword(s):  
Specific Gravity ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza B ◽  
Epidemic Season ◽  
Epidemiological Features ◽  
Influenza A H1n1 ◽  
Epidemic Period ◽  
Microcirculation Disturbance ◽  
Respiratory Viral Infections

Objective: to study the clinical and epidemiological features of influenza in children in the Stavropol Territory.Materials and methods: influenza prevalence is analyzed from 2015 to 2017 the paper used the data from the Territorial Rospotrebnadzor in the Stavropol Territory. We used the following methods: bibliographic, monographic description, epidemiological, analytical, statistical methods.Results: Among the deciphered acute respiratory viral infections, the specific gravity of influenza A (H1N1) 09 in 2016 reached 78%, and in 2017 influenza B prevailed – in 57,4% of children, and influenza A (H3N2) – in 42,6% of cases. In 2016 68,5% of children under 6 years of age, of all admitted, were hospitalized, and in 2017 – 83,86%. We presented the peculiarities of the course of influenza in different epidemic seasons.Conclusion: Unvaccinated children up to 6 years of age have the disease mainly in severe forms and with complications. The epidemic period began to increase in 2015–2016 at week 52, and in 2016–2017 from week 48, ended at week 13 and at week 17. At the epidemic of 2015–2016, intoxication syndrome with chills, microcirculation disturbance, catarrhal syndrome, ARDS prevailed in the clinical picture. The epidemic season of 2016–2017 was characterized by intoxication syndrome, encephalic reaction, hemorrhagic and myalgic syndromes.

scholarly journals Concomitant Infections of Influenza A H1N1 and Disseminated Cryptococcosis in an HIV Seropositive Patient

2015 ◽  
Vol 7 (02) ◽  
pp. 134-136 ◽  
Author(s):  
Ankit Gupta ◽  
Malini R Capoor ◽  
Sonal Gupta ◽  
Harish Chand Sachdeva
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Unusual Case ◽  
Viral Infections ◽  
Dual Infection ◽  
Seropositive Patient ◽  
Seropositive Individual ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections ◽  
Hiv Seropositive

ABSTRACTRespiratory viral infections, especially influenza have a potential to form a fatal association with cryptococcosis in the setting of compromised immunity. Considering the lethality of these two infections, we report an unusual case of dual infection of pandemic influenza A H1N1 and disseminated cryptococcosis in an HIV seropositive individual.

scholarly journals Endothelial Dysfunction through Oxidatively Generated Epigenetic Mark in Respiratory Viral Infections

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3067
Author(s):  
Spiros Vlahopoulos ◽  
Ke Wang ◽  
Yaoyao Xue ◽  
Xu Zheng ◽  
Istvan Boldogh ◽  
...  
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Care ◽  
Treatment Options ◽  
Pulmonary Complications ◽  
Epigenetic Mark ◽  
Host Immune System ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections ◽  
Syncytial Virus

The bronchial vascular endothelial network plays important roles in pulmonary pathology during respiratory viral infections, including respiratory syncytial virus (RSV), influenza A(H1N1) and importantly SARS-Cov-2. All of these infections can be severe and even lethal in patients with underlying risk factors.A major obstacle in disease prevention is the lack of appropriate efficacious vaccine(s) due to continuous changes in the encoding capacity of the viral genome, exuberant responsiveness of the host immune system and lack of effective antiviral drugs. Current management of these severe respiratory viral infections is limited to supportive clinical care. The primary cause of morbidity and mortality is respiratory failure, partially due to endothelial pulmonary complications, including edema. The latter is induced by the loss of alveolar epithelium integrity and by pathological changes in the endothelial vascular network that regulates blood flow, blood fluidity, exchange of fluids, electrolytes, various macromolecules and responses to signals triggered by oxygenation, and controls trafficking of leukocyte immune cells. This overview outlines the latest understanding of the implications of pulmonary vascular endothelium involvement in respiratory distress syndrome secondary to viral infections. In addition, the roles of infection-induced cytokines, growth factors, and epigenetic reprogramming in endothelial permeability, as well as emerging treatment options to decrease disease burden, are discussed.

scholarly journals Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1

2011 ◽  
Vol 38 (3) ◽  
pp. 739-742 ◽  
Author(s):  
M. A. Marcos ◽  
S. Ramon ◽  
A. Anton ◽  
E. Martinez ◽  
A. Vilella ◽  
...  
Keyword(s):  
Clinical Relevance ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza A H1n1 ◽  
Respiratory Viral Infections

scholarly journals Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season

2012 ◽  
Vol 18 (3) ◽  
pp. E55-E62 ◽  
Author(s):  
D. Viasus ◽  
E. Cordero ◽  
J. Rodríguez-Baño ◽  
J.A. Oteo ◽  
A. Fernández-Navarro ◽  
...  
Keyword(s):  
Clinical Features ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Influenza Season ◽  
Influenza A H1n1

Clinical Features of Hospitalized Adult Patients with Pneumonia in Novel Influenza A (H1N1) Infection

2010 ◽  
Vol 69 (1) ◽  
pp. 24 ◽  
Author(s):  
Chang Hoon Han ◽  
Yu Kyung Hyun ◽  
Yu Ri Choi ◽  
Na Young Sung ◽  
Yoon Seon Park ◽  
...  
Keyword(s):  
Clinical Features ◽  
Influenza A ◽  
Adult Patients ◽  
H1n1 Infection ◽  
Influenza A H1n1 ◽  
Novel Influenza A

Comparisons of Clinical Features among Influenza A (H1N1) and Seasonal Influenza A and B during 2009 to 2010 at a Single Institution

2011 ◽  
Vol 21 (4) ◽  
pp. 269 ◽  
Author(s):  
Tae-Gon Kang ◽  
Mi-Jin Kim ◽  
Byoung-Gwon Kim ◽  
Hye-Sung An ◽  
Hyun-Jin Yun ◽  
...  
Keyword(s):  
Clinical Features ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Single Institution ◽  
Influenza A H1n1

scholarly journals Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

2020 ◽  
Vol 92 (3) ◽  
pp. 50-55
Author(s):  
D. A. Lioznov ◽  
E. J. Karnaukhova ◽  
T. G. Zubkova ◽  
E. V. Shakhlanskaya
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Antiviral Drug ◽  
Main Group ◽  
Average Score ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

Sign in / Sign up

Export Citation Format

Share Document